When is the best time to stop taking venetoclax?

Venetoclax, an oral targeted drug targeting specific blood cancers, has shown significant efficacy in the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). However, patients often have many questions about how long they should be taken.

Venetoclax is often used in combination with drugs such as obinutuzumab or rituximab when treating CLL and SLL. The standard course of treatment with venetoclax under this combination regimen is usually 12 months. However, the specific dosage schedule needs to be individually adjusted by the doctor based on the patient's clinical response and tolerance. If the patient's condition is significantly relieved, the doctor may advise the patient to stop using venetoclax after completing the course of treatment and continue to monitor changes in the condition.

For patients with acute myeloid leukemia (AML), venetoclax is often used in combination with a hypomethylating drug. The length of treatment is relatively flexible and depends mainly on the patient's relief and the doctor's assessment. In many cases, patients may require ongoing treatment to maintain stable disease.

It is worth noting that long-term use of venetoclax may cause some side effects, such as neutropenia, anemia, and fatigue. Therefore, during the treatment process, doctors need to pay close attention to the patient's blood routine and other health indicators in order to adjust the dosage, extend the medication interval, or suspend treatment in a timely manner.

In summary, the duration of venetoclax administration varies depending on the patient's condition, treatment goals, and treatment response. Patients should be treated under the close guidance of a physician and regularly monitored and evaluated to ensure optimal treatment results and reduce the occurrence of side effects.